Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 66
Tirzepatide and kidney function in obesity
A 36-person real-world study found three months of tirzepatide improved eGFR in adults with obesity, with BMI change explaining about 19% of the kidney benefit.
Tirzepatide and platelet volume in obesity
A 60-person retrospective study found tirzepatide reduced mean platelet volume 0.94 fL with a 3.92 BMI-unit drop. What the data shows and where it falls short.
Tirzepatide vs GLP-1 agonists: MACE in T2D
A July 2026 JAHA study found tirzepatide linked to 25% lower MACE risk versus GLP-1 agonists in 16,402 matched patients with type-2 diabetes and ASCVD.
Retatrutide in Sweden: no approval yet
Retatrutide holds no EMA or Läkemedelsverket authorisation as of July 2026. Here is where the TRIUMPH trials stand and what that means for Swedish patients.
Semax in Sweden: regulatory status
Semax has no marketing authorisation in Sweden or the EU. Here is the Läkemedelslagen framework, what changed in 2025-2026, and who to ask.
Tesamorelin vs CJC-1295 with Ipamorelin
Both stacks pair a GHRH analog with ipamorelin, but tesamorelin and CJC-1295 have different half-lives and very different evidence bases.
Semaglutide in Pakistan: real-world data
A 30-week Pakistan study reports HbA1c reductions of 1.86 points and 7.84 kg mean weight loss with semaglutide in routine outpatient care.
Crunchometer: open-source feeding analysis
An open-source acoustic device for mice detects semaglutide appetite suppression and maps meal-tracking neurons in the lateral hypothalamus.
GLP-1 vs oral agents: insulin stop in T2D
A 2026 Annals study found GLP-1 agonists did not raise insulin discontinuation rates above SGLT-2 or DPP-4 inhibitors in 8,869 veterans with type 2 diabetes.
GLP-1 cancer risk vs bariatric surgery
A July 2026 study found GLP-1 receptor agonists were tied to lower colorectal and pancreatic cancer rates than bariatric surgery, not higher.
CRAVE study: GLP-1, food cravings, and diet
The CRAVE study tracked 28 adults on GLP-1 agonists for 24 weeks. Weight fell, diet quality did not improve, and micronutrient intake dropped.
How muscarine weakens heart contractions
Muscarine reduces cardiac contractile force in human atrial tissue only when cAMP is already elevated, including by GLP-1 agonists like semaglutide.